Photo from Aaron Goodman/X
Aug 18, 2023, 18:03
Aaron Goodman: How to choose between the 2 new BCMA directed bispecifics in myeloma?
Quoting on Aaron Goodman, Hematologist/Bone marrow transplanter at UCSD:
“How to choose between the 2 new (B-cell maturation antigen) BCMA directed bispecifics in myeloma?
Erlantamab is eventually given every 2 weeks as opposed to teclistamab every week for ever.
They will never be compared in RCT and both cost a huge amount of money this is all I have.
So I use erlantamab.”
Source: Aaron Goodman/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18
Dec 21, 2024, 11:12
Dec 21, 2024, 11:06